Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals

Melanoma Research

Volumn 6, Issue 6, 1996, Pages 419-425

  Jager E ^a   Ringhoffer, M ^a   Arand, M ^b   Karbach, J ^a   Jager D ^a   Ilsemann, C ^c   Hagedorn, M ^c   Oesch, F ^b   Knuth, A ^a  

^a KRANKENHAUS NORDWEST   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c KLINIKUM DARMSTADT   (Germany)

Author keywords

Cytotoxic T lymphocyte responses; Melanoma associated antigens

Indexed keywords

MELANOMA ANTIGEN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; IMMUNOTHERAPY; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

AMINO ACID SEQUENCE; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; HUMANS; MELANOMA; MEMBRANE GLYCOPROTEINS; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0030445149     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199612000-00003     Document Type: Article

References (34)

1. Knuth A, Wölfel T, Meyer zum Büschenfelde K-H. T cell responses to human malignant tumours. Cancer Surv 1992; 13: 39-52.
2. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647.
3. Van der Bruggen P, Szikora J-P, Boel P, et al. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601*. Eur J Immunol 1994; 24: 2134-2140.
4. Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179: 921-930.
5. Brichard V, Van Pel A, Wölfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178: 489-495.
6. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180: 35-42.
7. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91: 3525-3519.
8. Bakker AB, Schreurs MWJ, deBoer AJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179: 1005-1009.
9. Wang R-F, Robbins PF, Kawakami Y, et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995; 181: 799-804.
10. Anichini A, Maccalli C, Mortarini R, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993; 177: 989-998.
11. Wölfel T, Hauer M, Klehmann E, et al. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int J Cancer 1993; 55: 237-244.
12. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264: 716-719.
13. Bakker ABH, Schreurs MWJ, Tafazzul G, et al. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1 restricted anti-melanoma CTL line. Int J Cancer 1995; 62: 97-102.
14. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154: 3961-3968.
15. Wölfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994; 24: 759-764.
16. Kang XQ, Kawakami Y, El-Gamil M, et al. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol 1995; 155: 1343-1348.
17. Robbins PF, El-Gamil M, Kawakami Y, et al. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994; 54: 3124-3126.
18. Castelli C, Storkus WJ, Maeurer MJ, et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995; 181: 363-368.
19. Slingluff CLS, Cox AL, Stover JM, et al. Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res 1994; 54: 2731-2737.
20. Storkus WJ, Zeh HJZ, Maeurer MJ, et al. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol 1993; 151: 3719-3727.
21. Herin M, Lemoine C, Weynants P, et al. Production of stable cytolytic T cell clones directed against autologous human melanoma. Int J Cancer 1987; 39: 390-396.
22. Bernhard H, Karbach J, Wölfel T, et al. Cellular immune response to human renal cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T lymphocytes. Int J Cancer 1994; 59: 1-6.
23. Skipper JCA, Hendrickson RC, Gulden PH, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996; 183: 527-534.
24. Bodmer H, Ogg G, Gotch F, et al. Anti-HLA-A2 antibody-enhancement of peptide association with HLA-A2 as detected by cytotoxic T lymphocytes. Nature 1989; 342: 443-446.
25. Jäger E, Bernhard H, Romero P, et al. Generation of cytotoxic T cell responses with synthetic melanoma associated peptides in vivo: implications for tumor vaccines with melanoma associated antigens. Int J Cancer 1996; 66: 162-169.
26. Celis E, Tsai V, Crimi C, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994; 91: 2105-2109.
27. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995; 154: 2257-2265.
28. Visseren MJW, van Elsas A, van der Voort EIH, et al. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 1995; 154: 3991-3998.
29. Nanda NK, Sercarz EE. Induction of anti-self-immunity to cure cancer. Cell 1995; 82: 13-17.
30. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91: 6458-6462.
31. Boon T, Gajewski TF, Coulie P. From defined human tumor antigens to effective immunization? Immunol Today 1995; 16: 334-336.
32. Brasseur F, Rimoldi D, Lienard D, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995; 63: 375-380.
33. Chen YT, Stocken E, Tsang S, et al. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 1995; 92: 8125-8129
34. Adema GJ, De Boer AJ, van't Hullenaar R, et al. Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50 and HMB-45 are encoded by a single cDNA. Am J Pathol 1993; 143: 1579-1585.